Compare Outset Medical, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 61 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.56
-58.05%
0.48
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Dec 2025)
Net Profit:
-19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.29%
0%
7.29%
6 Months
-76.13%
0%
-76.13%
1 Year
-66.35%
0%
-66.35%
2 Years
-88.17%
0%
-88.17%
3 Years
-81.53%
0%
-81.53%
4 Years
-99.44%
0%
-99.44%
5 Years
-99.54%
0%
-99.54%
Outset Medical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.06%
EBIT Growth (5y)
7.48%
EBIT to Interest (avg)
-35.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.48
Tax Ratio
0.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.48
EV to EBIT
0.14
EV to EBITDA
0.16
EV to Capital Employed
-0.17
EV to Sales
-0.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-58.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 35 Schemes (42.73%)
Foreign Institutions
Held by 56 Foreign Institutions (9.91%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
28.90
29.40
-1.70%
Operating Profit (PBDIT) excl Other Income
-16.50
-14.80
-11.49%
Interest
3.40
3.50
-2.86%
Exceptional Items
-0.30
0.00
Consolidate Net Profit
-19.50
-17.80
-9.55%
Operating Profit Margin (Excl OI)
-600.70%
-537.30%
-6.34%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -1.70% vs -6.37% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -9.55% vs 3.78% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
119.50
113.70
5.10%
Operating Profit (PBDIT) excl Other Income
-62.40
-102.10
38.88%
Interest
14.00
23.90
-41.42%
Exceptional Items
-7.70
-5.60
-37.50%
Consolidate Net Profit
-81.70
-128.00
36.17%
Operating Profit Margin (Excl OI)
-558.40%
-948.40%
39.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.10% vs -12.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 36.17% vs 25.93% in Dec 2024
About Outset Medical, Inc. 
Outset Medical, Inc.
Pharmaceuticals & Biotechnology
Outset Medical, Inc. is a medical technology company. The Company offers Tablo, a dialysis machine. Tablo offers acute and chronic dialysis. Tablo produces dialysate that’s customized to the patient’s prescription. Its touchscreen guidance and animated instructions enables to train new users. Tablo has integrated water purification and produces dialysis on demand. The other features of Tablo include integrated blood pressure cuff and automated saline bolus and tracking. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels and allows providers to a single platform from the hospital to the home. The three subtypes of hemodialysis that are used in the hospital are Intermittent Hemodialysis (IHD), Slow Low Efficiency Dialysis (SLED) and CRRT. IHD is used at the bedside or an inpatient dialysis unit outside of the ICU, while SLED and CRRT are used in the ICU.
Company Coordinates 
Company Details
3052 Orchard Drive , SAN JOSE CA : 95134
Registrar Details






